Toggle navigation
About
Abstract
Editorial Board
Subscription & Newsletter
Contact
Issues
This issue
17-3
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
17-3
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Journals
Journal #483
advertisement
Eye
21
Showing records 1 to 21 |
Display all abstracts in
Eye
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Srinivasan S
Eye
2016; 30: 362-368
66513
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Quartilho A
Eye
2016; 30: 602-607
66602
Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Groen F
Eye
2016; 30: 473-480
66340
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Olmos LC
Eye
2016; 30: 463-472
65881
A view on glaucoma-are we seeing it clearly?
Crabb DP
Eye
2016; 30: 304-313
66513
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Simkiss P
Eye
2016; 30: 602-607
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Choudhari NS
Eye
2016; 30: 362-368
66340
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Sayed MS
Eye
2016; 30: 463-472
66602
Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Ramdas W; de Hoog J
Eye
2016; 30: 473-480
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Baskaran M
Eye
2016; 30: 362-368
66340
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Moraczewski AL
Eye
2016; 30: 463-472
66513
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Zekite A
Eye
2016; 30: 602-607
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
George RJ
Eye
2016; 30: 362-368
66602
Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Vingerling JR
Eye
2016; 30: 473-480
66513
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Xing W
Eye
2016; 30: 602-607
66340
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Gedde SJ; Rosenfeld PJ
Eye
2016; 30: 463-472
66602
Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Rothova A
Eye
2016; 30: 473-480
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Shantha B
Eye
2016; 30: 362-368
66513
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Wormald R; Bunce C
Eye
2016; 30: 602-607
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Vijaya L
Eye
2016; 30: 362-368
66340
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Shi W; Feuer WJ; Lee RK
Eye
2016; 30: 463-472
Issue
17-3
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept